From left to right Tasca Therapeutics co-founders David Fisher, Milenko Cicmil, Xu Wu (Credit: Rick Bern Photography)
December 10, 2024 04:01 AM ESTUpdated December 11, 08:55 AM
Financing
Startups

New on­col­o­gy biotech launch­es with $52M in its pock­et

Kyle LaHucik

Senior Reporter

A small mol­e­cule can­cer biotech broke cov­er on Tues­day with a $52 mil­lion Se­ries A to take on a “unique lip­i­da­tion pock­et” and get in­to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Bio­gen makes cuts across its re­search unit, shift­ing fo­cus to ‘ex­ter­nal op­por­tu­ni­ties’

Bio­Marin turns to ex-Roche deal­mak­er James Sabry to build ‘next ver­sion’ of 27-year-old com­pa­ny

Chi­na's biotech boom is threat­en­ing US drug­mak­er­s' dom­i­nance

An­thos' de­tailed mid-stage da­ta back its an­ti­co­ag­u­lant, but can the drug suc­ceed where Bay­er's failed?

Te­va’s MS drug and gener­ics to add black box warn­ing for ana­phy­lax­is

sponsored

Fu­el­ing More Break­throughs: Man­u­fac­tur­ing In­no­va­tion to Ex­pand Gene Ther­a­py’s Reach

A service from the Financial Times